No evidence of somatic FGFR3 mutation in various types of carcinoma
- PMID: 11526491
- DOI: 10.1038/sj.onc.1204651
No evidence of somatic FGFR3 mutation in various types of carcinoma
Abstract
Germline specific point mutations in the gene encoding fibroblast growth factor receptor 3 (FGFR3) are associated with autosomal dominant human skeletal dysplasia and craniosynostosis syndromes. Mutations identical to the germinal activating mutations found in severe skeletal dysplasias have been identified in certain types of cancer: at low frequency in multiple myeloma and cervix carcinoma and at high frequency in bladder carcinoma. We analysed, by SSCP and sequencing, the prevalence of FGFR3 mutations in 116 primary tumours of various types (upper aerodigestive tract, oesophagus, stomach, lung and skin). The regions analysed encompassed all FGFR3 point mutations previously described in severe skeletal dysplasia and cancers. No mutations were detected in the tumour types examined, suggesting that FGFR3 mutations are restricted to a few tumour types, the evidence to date suggesting that they are very specific to bladder carcinomas.
Similar articles
-
Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders.Eur J Hum Genet. 2002 Dec;10(12):819-24. doi: 10.1038/sj.ejhg.5200883. Eur J Hum Genet. 2002. PMID: 12461689
-
Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma.Oncogene. 2001 Feb 8;20(6):686-91. doi: 10.1038/sj.onc.1204110. Oncogene. 2001. PMID: 11314002
-
Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans.Hum Mol Genet. 2005 May 1;14(9):1153-60. doi: 10.1093/hmg/ddi127. Epub 2005 Mar 16. Hum Mol Genet. 2005. PMID: 15772091
-
Craniosynostosis and skeletal dysplasias: fibroblast growth factor receptor defects.Proc Assoc Am Physicians. 1996 Jan;108(1):19-24. Proc Assoc Am Physicians. 1996. PMID: 8834060 Review. No abstract available.
-
Predicting favourable prognosis of urothelial carcinoma: gene expression and genome profiling.Curr Opin Urol. 2009 Sep;19(5):516-21. doi: 10.1097/MOU.0b013e32832eb45f. Curr Opin Urol. 2009. PMID: 19553819 Review.
Cited by
-
New Directions and Challenges in Targeted Therapies of Advanced Bladder Cancer: The Role of FGFR Inhibitors.Cancers (Basel). 2022 Mar 10;14(6):1416. doi: 10.3390/cancers14061416. Cancers (Basel). 2022. PMID: 35326568 Free PMC article. Review.
-
A genomics-based classification of human lung tumors.Sci Transl Med. 2013 Oct 30;5(209):209ra153. doi: 10.1126/scitranslmed.3006802. Sci Transl Med. 2013. PMID: 24174329 Free PMC article.
-
Joint association of polymorphism of the FGFR4 gene and mutation TP53 gene with bladder cancer prognosis.Br J Cancer. 2006 Dec 4;95(11):1455-8. doi: 10.1038/sj.bjc.6603456. Epub 2006 Nov 7. Br J Cancer. 2006. PMID: 17088904 Free PMC article.
-
FGFR3IIIS: a novel soluble FGFR3 spliced variant that modulates growth is frequently expressed in tumour cells.Br J Cancer. 2003 Oct 6;89(7):1276-84. doi: 10.1038/sj.bjc.6601249. Br J Cancer. 2003. PMID: 14520460 Free PMC article.
-
Overexpression of KLF13 and FGFR3 in oral cancer cells.Cytogenet Genome Res. 2010 Jun;128(4):192-8. doi: 10.1159/000308303. Epub 2010 Jun 2. Cytogenet Genome Res. 2010. PMID: 20539070 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
